A 58% reduction in the risk of death is a number that rarely appears in solid tumor oncology, and in extensive-stage small cell lung cancer, a disease where median overall survival had been measured in months rather than years, it carries particular weight. Interim Phase 3 results from the DeLLphi-305 trial, presented at the ESMO 2026 Presidential Symposium and simultaneously published in the New England Journal of Medicine, showed that tarlatamab (IMDELLTRA) plus durvalumab (IMFINZI) as first-line maintenance extended median overall survival to 21.1 months compared with 12.7 months for durvalumab alone, a hazard ratio of 0.42 at a median follow-up of about 16 months.
The one-year survival gap tells the story concretely: nearly 80% of patients on the combination were alive at 12 months versus 53% on durvalumab alone. Progression-free survival widened even more sharply, from 1.9 months to 7.4 months, a 66% reduction in the risk of progression or death. Response rates followed the same pattern: roughly one in four patients on the combination achieved an objective response compared with roughly one in 25 on durvalumab alone. Critically, the survival benefit held in patients with brain metastases and liver metastases, two subgroups that historically drive the worst outcomes in this disease.
The safety picture matters for trial design and eventual clinical adoption. Grade 3 or higher treatment-related adverse events occurred in about 21% of patients on the combination versus 11% on durvalumab alone. Cytokine release syndrome appeared in roughly half of tarlatamab-treated patients but was Grade 1 in most cases; only one Grade 3 event was recorded and no Grade 4 or higher events. The protocol required monitoring for one to two hours post-infusion on Cycle 1 Days 1 and 8, or six to eight hours in certain regions including Europe, a logistical consideration sites will need to plan for if this combination moves toward approval. Tarlatamab already carries accelerated FDA approval in previously treated ES-SCLC based on Phase 2 response data; these Phase 3 OS results in the first-line maintenance setting put regulatory submissions in a meaningfully different position.
Supporting data presented alongside DeLLphi-305 add durability context. Updated DeLLphi-303 results at 30.8 months of median follow-up showed median OS of 37.9 months from the start of first-line maintenance, with 58% of patients alive at two years. The Phase 3 DeLLphi-305 OS benchmark of 21.1 months is measured from randomization at maintenance start, meaning absolute survival from initial diagnosis is longer still. The number to watch now is how quickly regulatory submissions translate into a label expansion, and whether the post-infusion monitoring requirement narrows the setting to specialist centers or proves manageable in community oncology.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
